Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 155

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 155
---
 the year ended December 31, 2024:

| Name                |     | Grant          
 Date           |     | Stock   
 Options |        |     | Exercise 
 Price    |      |     | Expiration     
 Date           |
|:--------------------|:----|:---------------|:----|:--------|-------:|:----|:---------|-----:|:----|:---------------|
| Mr. Keith Valentine |     | September 2015 |     |         | 37,500 |     | $        | 3.97 |     | September 2025 |

As
approved by our board of directors, subject to and following the completion of this offering, we intend to grant options to purchase
up to 39,295 Ordinary Shares and up to 465,533 Ordinary Shares to Mr. Pini Ben-Elazar and Dr. Ehud Geller, respectively. The options
will have an exercise price of NIS 0.001 and will expire on the ten-year-anniversary of the grant date.

In
addition, on March 20, 2025, our shareholders approved a one-time payment to Mr. Ehud Geller in the amount of $500,000 in consideration
of his services to the Company since 2019, for which he has not received compensation. The payment is conditional upon the closing of
this offering. Subsequent to the shareholders’ approval of the payment, Mr. Geller agreed that $250,000 will be paid upon completion
of this offering and the remainder will be deferred until the Company completes a future fundraising.

Engagement Agreements with Executive Officers

We
have entered into written engagement or consultancy agreements with each of our executive officers, including our Chairman, Dr. Ehud
Geller and our Chief Executive officer, Dr. Eli Hazum. These agreements are terminable by either party upon 60 days’ prior written
notice. All of these agreements contain customary provisions regarding noncompetition, confidentiality of information and assignment
of inventions. None of such agreements contain any terms providing for severance benefits. However, the enforceability of the noncompetition
provisions may be limited under applicable law. In addition, we intend to enter into indemnification agreements, subject to the listing
of our securities on the NYSE American, with each executive officer and director pursuant to which we will indemnify each of them up
to a certain amount and to the extent that these liabilities are not covered by directors and officers’ insurance.

We